Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Friday, March 29, 2024 · 699,616,372 Articles · 3+ Million Readers

The ALRT Diabetes Management System in Action

New video presentation shows how health care providers use the features of ALRT's Diabetes Management System to support patients with Type 2 Diabetes

/EINPresswire.com/ -- RICHMOND, VA--(Marketwired - October 23, 2017) - Following the recent FDA clearance of the Company's Insulin Dose Adjustment feature and release of its patent pending Predictive A1C innovation, ALR Technologies Inc. ("ALRT" or the "Company") has released a new video presentation to show how health care providers are supported by the ALRT Diabetes Management System.

The latest video titled "Details of the ALRT Diabetes Management System" provides a tour of the ALRT diabetes management system from the perspective of a healthcare provider monitoring a group of diabetes patients under his or her care. The healthcare provider is able to view the progress and history of patient's blood glucose date and the Predictive A1C trend for specific patients, and make decisions on adjustment of medicines within the system. ALRT provides in an integrated view, dosage information for all major diabetes medicines as well as the American Diabetes Association and American Association of Clinical Endocrinologists clinical guidelines for insulin dosage.

"Details of the ALRT Diabetes Management System" is the final video in a series of six videos released by ALRT last week, which highlight key features of the ALRT diabetes management system. To view the videos please go to the Company's YouTube channel -- www.youtube.com/ALRTechnologies.

Note to Readers: screenshots of the ALRT Diabetes Management System include names of medicines prescribed for the treatment of Type 2 Diabetes, including the following:

Metformin and Metformin extended release
Carbophage SR, Fortamet, Glucophage XR, Glumetza, Riomet

GLP-1-RA
Adlyxin, Bydureon, Byetta, Tanzeum, Trulicity, Victoza

GLP-1-RA Combinations
Soliqua 100-33, Xultophy

AGI
Precose, Glyset

SGL2-I
Farxiga, Invokana, Jardiance

SGL2-I Combinations
Invokamet, Synjardy, Xigduo, Glyxambi

Sulfa
Amaryl, Diabeta, Glucotrol, Micronase

Sulfa Combinations
Amaryl M, Glucovance, Metaglip, Avandaryl, Duetact

GLN
Glufast, Prandin, Starlix

GLN Combinations
PrandiMet

DPP-4-I
Januvia, Nesina, Onglyza, Tradjenta

DPP-4-I Combinations
Janumet, Jentadueto, Kazano, Kombiglyze XR, Glyxambi, Oseni

TZD
Actos, Avandia

TZD Combinations
Actoplus Met, Avandamet, Oseni, Avandaryl, Duetact

INSULINS
Intermediate
Humulin N, Novolin N

Long acting
Basaglar, Lantus, Levemir, Toujeo, Tresiba

Premixed
Humalog Mix 50/50, Humalog Mix 75/25, Humulin 70/30, Novolin 70/30, Novolog Mix 70/30

Rapid acting
Afrezza, Apidra, Flasp, Humalog, Novolog

Short acting
Humulin R, Novolin R

About ALR Technologies Inc.
ALR Technologies is a medical device company providing an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters. The System processes and streamlines collected data to support clinicians and caregivers to improve patient outcomes and assist health plans to optimize their investments in chronic disease care. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. More information about ALR Technologies, Inc. can be found at www.alrt.com.

Contact:
Ken Robulak:
1.877.257.8242
email: info@alrt.com

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release